ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

Molecular Cancer Therapeutics

Volumn 7, Issue 10, 2008, Pages 3265-3274

  Ackler, Scott ^a   Xiao, Yu ^a   Mitten, Michael J ^a   Foster, Kelly ^a   Oleksijew, Anatol ^a   Refici, Marion ^a   Schlessinger, Sally ^a   Wang, Baole ^a   Chemburkar, Sanjay R ^a   Bauch, Joy ^a   Tse, Christin ^a   Frost, David J ^a   Fesik, Stephen W ^a   Rosenberg, Saul H ^a   Elmore, Steven W ^a   Shoemaker, Alex R ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 263; ANTINEOPLASTIC AGENT; CASPASE 3; LIPOCORTIN 5; MACROLIDE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN BCL 2; PROTEIN BID; RAPAMYCIN; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL KILLING; CONTROLLED STUDY; CYTOSTASIS; DRUG ACTIVITY; DRUG RESPONSE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TUMOR REGRESSION; XENOGRAFT; ANIMAL; CELL CYCLE; CELL DEATH; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MOUSE MUTANT; PATHOLOGY; REMISSION; TUMOR CELL LINE;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MICE, SCID; REMISSION INDUCTION; SIROLIMUS; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 55749084366     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0268     Document Type: Article

References (36)

1. Surveillance, Epidemiology and End Results [homepage on the Internet]. Bethesda: National Cancer Institute; c1973-2007 [updated 2007 Dec 18; cited 2008 Jan 2]. Cancer stats fact sheet, non-Hodgkin's lymphoma [top of page]. Available from: http://seer.cancer.gov/statfacts/html/nhl.html.
2. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cell with the t(14;18) chromosome translocation. Science 1984;226:1027-9.
3. Wei MC. Bcl-2-related genes in lymphoid neoplasia. Int J Hematol 2004;80:205-9.
4. L from NMR and parallel synthesis. J Med Chem 2006;49:656-63.
5. Elmore SW. ABT-263: an orally bioavailable Bcl-2 family protein inhibitor. Proceedings AACR 2007.
6. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-8.
7. Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharm Ther 2007;82: 381-8.
8. Tsang CK, Qi H, Liu LF, Zheng XF. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 2007;12: 112-24.
9. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-88.
10. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23:5347-56.
11. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356: 2271-81.
12. Asnaghi L, Calastretti A, Bevilacqua A, et al. Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene 2004;23:5781-91.
13. Vega F, Medeiros LJ, Leventaki V, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 2006;66:6589-97.
14. Wei G, Twomey D, Lamb J, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006;10:331-42.
15. L ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity. Oncogene 2005;24:3348-57.
16. Calastretti A, Rancati F, Ceriani MC, Asnaghi L, Canti G, Nicolin A. Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect. Eur J Cancer 2001;37:2121-8.
17. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
18. Haycock JW. Polyvinylpyrrolidone as a blocking agent in immunochemical studies. Anal Biochem 1993;208:397-9.
19. L potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 2006;66:8731-9.
20. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105.
21. Bertoni F, Rinaldi A, Zucca E, Cavalli F. Update on the molecular biology of mantle cell lymphoma. Hematol Oncol 2006;24:22-7.
22. Shoemaker AR, Mitten MJ, Adickes J, et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 2008;14:3268-77.
23. Seeliger H, Guba M, Kleespies A, Jauch KW, Bruns CJ. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007;26: 611-21.
24. del Bufalo D, Ciuffreda L, Trisciuoglio D, et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006;66:5549-54.
25. Phung TL, Ziv K, Dabydeen D, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006;10:159-70.
26. Gera JF, Mellinghoff IK, Shi Y, et al. AKT activity determined sensitivity to mTOR inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004;279:2737-46.
27. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994;372:570-3.
28. Kip1) of cyclin-dependent kinase 4 activation. Cell 1994;79:487-96.
29. Maddika S, Ande SR, Panigrahi S, et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 2007;10:13-29.
30. Wendel HG, Malina A, Zhao Z, et al. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res 2006;66:7639-46.
31. Aguirre D, Boya P, Bellet D, et al. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 2004;9:797-805.
32. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66: 1500-8.
33. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179-83.
34. Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 2006;169:2171-80.
35. Shroff EH, Snyder C, Chandel NS. Bcl-2 family members regulate anoxia-induced cell death. Cell Cycle 2007;6:807-9.
36. del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007; 117:112-21.